More options, more questions in the management of early relapsed and/or refractory multiple myeloma [0.03%]
复发和/或难治性多发性骨髓瘤早期治疗选择及疑问更多了
Carlyn Rose Tan,Sham Mailankody
Carlyn Rose Tan
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management [0.03%]
抗体药物偶联物和免疫检查点抑制剂抗体药物偶联物联合用药的临床毒性：机制、模式和管理
Solange Peters,Petros Grivas,Christophe Massard et al.
Solange Peters et al.
Antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) have reshaped cancer therapy both as monotherapy and in combination. However, these drug classes have toxicity profiles that, despite arising from different biological ...
Hira Mian,Luciano J Costa,Mohamad Mohty et al.
Hira Mian et al.
De-escalation of therapy constitutes a new phase in the development of therapeutic approaches for patients with multiple myeloma (MM) and is aimed at maintaining durable disease control while reducing the toxicity and burden associated with...
Klaus Pantel,Doryan Masmoudi,Catherine Alix-Panabières
Klaus Pantel
Analysis of tissue biopsy samples is the gold-standard approach to cancer diagnosis and patient selection for biomarker-guided therapies. Although spatial analyses of tumour tissue can provide important insights into local antitumour immune...
Crossover does not confound, it informs: 177lutetium-PSMA-617 as an example [0.03%]
跨界研究不是误导，而是提供信息：以177Lu-PSMA-617为例
Martin W Schoen,Tito Fojo,Johann de Bono
Martin W Schoen
The future of ciltacabtagene autoleucel in multiple myeloma has just begun [0.03%]
Ciltacabtagene Autoleucel在多发性骨髓瘤中的治疗前景刚刚开始
Maximilian Merz,Nico Gagelmann
Maximilian Merz
Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma [0.03%]
Ciltacabtagene Autoleucel宣告多发性骨髓瘤固定疗程治疗的到来
Ghulam Rehman Mohyuddin,Edward R Scheffer Cliff,Rajshekhar Chakraborty
Ghulam Rehman Mohyuddin